Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
BACKGROUND AND OBJECTIVE
Omalizumab is a human anti-IgE antibody approved for the treatment of severe allergic asthma (SAA). However, its effectiveness in SAA associated with chronic rhinosinusitis with nasal polyposis (CRSNP+) is less well documented. Objective: The aim of this study was to evaluate the real-life effectiveness of omalizumab in patients with SAA and CRSNP+ who tolerated and did not tolerate aspirin.


METHODS
We performed a retrospective, observational, multicenter, real-life study of patients with SAA and CRSNP+ treated with omalizumab for 6 months. Asthma outcome parameters (symptoms, number of salbutamol rescues/wk, number of moderate/severe exacerbations, Asthma Control Test score, and lung function), sinonasal outcome parameters (symptoms, number of episodes of acute rhinosinusitis, sinus computed tomography images, nasal polyps endoscopy score), and serum eosinophil levels were analyzed 6 months before and after treatment with omalizumab.


RESULTS
Twenty-four adult patients were included (9 with documented aspirin intolerance). All respiratory parameters were significantly improved by the treatment. In parallel, a significant improvement was observed in sinonasal clinical outcomes and sinus computed tomography images, with no major effect on the nasal polyps endoscopy score. The serum eosinophil count decreased significantly after 6 months of treatment with omalizumab.


CONCLUSION
Treatment of SAA with omalizumab improves the outcome of associated CRSNP+, thus supporting the concept of a "one airway disease".
['Tiotiu|A|A|', 'Oster|J P|JP|', 'Roux|P R|PR|', 'Nguyen Thi|P L|PL|', 'Peiffer|G|G|', 'Bonniaud|P|P|', 'Dalphin|J C|JC|', 'de Blay|F|F|']
D000328:Adult D018927:Anti-Asthmatic Agents D001249:Asthma D004804:Eosinophils D005260:Female D006801:Humans D007958:Leukocyte Count D008297:Male D008875:Middle Aged D009298:Nasal Polyps D000069444:Omalizumab D012189:Retrospective Studies D065631:Rhinitis, Allergic D016896:Treatment Outcome
Effectiveness of omalizumab Severe allergic asthma CRSNP+